A few weeks ago, HERAN hosted its annual Investor Day at "Kasteel van Brasschaat". We were pleased to host many investors and stakeholders. During the event, our Managing Partner, Katleen Vandersmissen provided an update on the HERAN HealthTech Fund I and shared her vision for the future of HERAN Partners.
Exit UgenTec to Summa Equity
During the last year, several important milestones were achieved. Firstly, our portfolio company UgenTec was acquired by SummaEquity. Following an impressive growth trajectory, UgenTec demonstrated strong continued commercial uptake of its FastFinder platform, a Software-as-a-Service solution that allows labs to standardise, automate, and add an intelligent layer to their molecular testing workflows. With Summa Equity on board as reference shareholder, UgenTec will be able to capitalise on its strong track record of growth and innovation.
20 Mio EUR round for LynxCare
On the portfolio side, LynxCare successfully raised a 20Mio EUR round from existing and new investors, MTIP and Elaia. The financing allows LynxCare to further fund the commercial roll-out of their Real World Evidence business model on an international scale. We are looking forward to fostering growth and driving the company in becoming an indispensable partner in unlocking insights from large datasets.
New investment: Aspect Analytics
Over the summer, we closed the investment in Aspect Analytics, a Belgium-based bioinformatics solutions provider with a focus on spatial multi omics space and with sound experience in mass spectrometry imaging. As we are strong believers in the potential and the further uptake of spatial and multi omics techniques & insights in the Life Sciences industry, we are keen to support Aspect Analytics in becoming a frontrunner in this up and coming domain.
We will continue to build out our portfolio and strive to become a preferred partner for high-growth ventures within the healthcare space.
At the end of the plenary session, we invited Stein Aerts, Professor of Computational Biology at the KU Leuven, to take the stage and speak about novel analysis technologies and bioinformatics which can create insights in health and diseases.
We hope to once again host many invitees to our event next year!